Karus Therapeutics Ltd, a British biotech developing small molecules for cancer, has appointed Hilary McElwaine-Johnn to the position of chief medical officer. Dr McElwaine-Johnn is a physician with more than 25 years of experience in drug development. She was most recently CMO at the cancer gene therapy company PsiOxus Therapeutics Ltd and before that, CMO at Vantia Therapeutics Ltd. She completed her Bachelor of Science and medical degrees at Imperial College London and St Mary’s Hospital Medical School respectively.
Karus currently has two products in Phase 1 development: an HDAC6 inhibitor for solid tumours and a PI3K inhibitor for B cell lymphoma.
Karus announced the appointment on 17 July 2019.
Copyright 2019 Evernow Publishing Ltd